ITUS CORPORATION (NASDAQ:ITUS) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report is the form of presentation that ITUS Corporation (“we,” “us,” “our,” or the “Company”) used in connection with its presentations to certain potential investors in the Company at an event hosted by WallStreet Research in Los Angeles CA on May 31, 2017.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No. Description
99.1 Presentation
About ITUS CORPORATION (NASDAQ:ITUS)
ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body’s immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients. ITUS CORPORATION (NASDAQ:ITUS) Recent Trading Information
ITUS CORPORATION (NASDAQ:ITUS) closed its last trading session 00.000 at 0.840 with 72,301 shares trading hands.